Another study conducted by Jeng et al. [149] verified that a high grade of the pre-treatment serum ALB level combined with a pre-treatment hepatitis B virus (HBV) pre-S2 gene deletion mutation as an independent predictor for worse RFS in HCC patients undergoing curative surgical resection. The gene discussed is ALB; the disease is hepatocellular carcinoma.